The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.22, no.1, pp.8-14, 2012 (SCI-Expanded)
- Publication Type: Article / Article
- Volume: 22 Issue: 1
- Publication Date: 2012
- Doi Number: 10.4999/uhod.12004
- Journal Name: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Page Numbers: pp.8-14
- Istanbul University Affiliated: Yes
Abstract
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.